AU2015292889C1 - Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases - Google Patents

Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases Download PDF

Info

Publication number
AU2015292889C1
AU2015292889C1 AU2015292889A AU2015292889A AU2015292889C1 AU 2015292889 C1 AU2015292889 C1 AU 2015292889C1 AU 2015292889 A AU2015292889 A AU 2015292889A AU 2015292889 A AU2015292889 A AU 2015292889A AU 2015292889 C1 AU2015292889 C1 AU 2015292889C1
Authority
AU
Australia
Prior art keywords
protein
fusion protein
cells
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
AU2015292889A
Other languages
English (en)
Other versions
AU2015292889B2 (en
AU2015292889A1 (en
Inventor
Jeffrey Greve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delinia Inc
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015292889(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of AU2015292889A1 publication Critical patent/AU2015292889A1/en
Application granted granted Critical
Publication of AU2015292889B2 publication Critical patent/AU2015292889B2/en
Priority to AU2020203480A priority Critical patent/AU2020203480A1/en
Priority to AU2022204946A priority patent/AU2022204946A1/en
Publication of AU2015292889C1 publication Critical patent/AU2015292889C1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015292889A 2014-07-21 2015-07-20 Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases Withdrawn - After Issue AU2015292889C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020203480A AU2020203480A1 (en) 2014-07-21 2020-05-27 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2022204946A AU2022204946A1 (en) 2014-07-21 2022-07-11 Molecules that selectively activate regulatory t cells for the treatment of autoimmune disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21
US61/999,241 2014-07-21
PCT/US2015/041177 WO2016014428A2 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203480A Division AU2020203480A1 (en) 2014-07-21 2020-05-27 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (3)

Publication Number Publication Date
AU2015292889A1 AU2015292889A1 (en) 2016-01-28
AU2015292889B2 AU2015292889B2 (en) 2020-02-27
AU2015292889C1 true AU2015292889C1 (en) 2023-01-19

Family

ID=55163946

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015292889A Withdrawn - After Issue AU2015292889C1 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
AU2020203480A Abandoned AU2020203480A1 (en) 2014-07-21 2020-05-27 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2022204946A Withdrawn AU2022204946A1 (en) 2014-07-21 2022-07-11 Molecules that selectively activate regulatory t cells for the treatment of autoimmune disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020203480A Abandoned AU2020203480A1 (en) 2014-07-21 2020-05-27 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2022204946A Withdrawn AU2022204946A1 (en) 2014-07-21 2022-07-11 Molecules that selectively activate regulatory t cells for the treatment of autoimmune disease

Country Status (22)

Country Link
US (6) US20170051029A1 (enExample)
EP (2) EP3172227B9 (enExample)
JP (2) JP6768633B2 (enExample)
KR (1) KR102493543B1 (enExample)
CN (2) CN114133456A (enExample)
AU (3) AU2015292889C1 (enExample)
CA (1) CA2954847A1 (enExample)
DK (1) DK3172227T3 (enExample)
EA (2) EA038361B1 (enExample)
ES (1) ES2763198T3 (enExample)
GB (1) GB2538666A (enExample)
HU (1) HUE046065T2 (enExample)
IL (3) IL289475B2 (enExample)
LT (1) LT3172227T (enExample)
MX (2) MX378790B (enExample)
PL (1) PL3172227T3 (enExample)
PT (1) PT3172227T (enExample)
RS (1) RS59789B1 (enExample)
SG (2) SG11201700514SA (enExample)
SI (1) SI3172227T1 (enExample)
WO (1) WO2016014428A2 (enExample)
ZA (1) ZA201700344B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
SG11201700514SA (en) * 2014-07-21 2017-02-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SI3482766T1 (sl) 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017359172A1 (en) * 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
WO2018112069A1 (en) * 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
AU2018234628B2 (en) 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
EP3604538A4 (en) * 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
SG11202004581PA (en) 2017-11-21 2020-06-29 Univ Leland Stanford Junior Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7250790B2 (ja) * 2017-12-06 2023-04-03 パンディオン・オペレーションズ・インコーポレイテッド Ｉｌ－２ムテインおよびその使用
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019131964A1 (ja) 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
WO2019147837A2 (en) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
TW202513581A (zh) 2018-03-28 2025-04-01 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
EP3552738B1 (en) * 2018-04-12 2024-07-31 Sandvik Machining Solutions AB A method of producing an additive manufactured object
CN112638406B (zh) 2018-06-22 2025-04-22 科优基因公司 白介素-2变体及其使用方法
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
EP3827079A1 (en) 2018-07-25 2021-06-02 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3172359A1 (en) 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
AU2019409196A1 (en) * 2018-12-21 2021-06-17 Jiangsu Hengrui Medicine Co., Ltd. Human interleukin-2 variant or derivative thereof
CN120157766A (zh) 2019-02-01 2025-06-17 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CA3129834A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US20220306714A1 (en) * 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
CA3160466A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
US11718654B2 (en) 2019-11-05 2023-08-08 Medikine, Inc. IL-2R-βγ binding compounds
JP2023505590A (ja) * 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
WO2021127495A1 (en) * 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
BR112022014401A2 (pt) 2020-02-03 2022-11-16 Medikine Inc Ligante de il-7r-alfa, composto, composição farmacêutica e ácido nucleico
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
IL302114A (en) 2020-10-29 2023-06-01 Bristol Myers Squibb Co Fusion proteins for the treatment of disease
WO2022100684A1 (zh) 2020-11-13 2022-05-19 江苏恒瑞医药股份有限公司 一种包含人白细胞介素2变体或其衍生物的药物组合物及其用途
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
IL307481A (en) 2021-04-09 2023-12-01 Selecta Biosciences Inc Synthetic nanocarriers containing an immune system suppressor combined with IL-2 receptor agonists with high affinity for increasing immune tolerance
JP2024533848A (ja) 2021-10-06 2024-09-12 イルトゥー・ファルマ 炎症組織へのターゲティング特異性を備えるインターロイキン２キメラコンストラクト
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN115322260A (zh) * 2022-06-13 2022-11-11 杭州高田生物医药有限公司 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
EP4587043A1 (en) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Interleukin-2 for use in treating autism spectrum disorder
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107417A1 (en) * 2011-02-10 2012-08-16 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
EP1421187B1 (en) 2001-07-27 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Systems for in vivo site-directed mutagenesis using oligonucleotides
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
EP2133362B1 (en) * 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
JP5766124B2 (ja) * 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
AR075896A1 (es) * 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
ES2638521T5 (es) * 2010-03-05 2021-03-02 Univ Johns Hopkins Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
SG11201700514SA (en) 2014-07-21 2017-02-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107417A1 (en) * 2011-02-10 2012-08-16 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Also Published As

Publication number Publication date
WO2016014428A3 (en) 2016-03-24
GB2538666A (en) 2016-11-23
DK3172227T3 (da) 2019-12-02
US20210047382A1 (en) 2021-02-18
EA202190903A3 (ru) 2021-12-31
US20170037102A1 (en) 2017-02-09
AU2015292889B2 (en) 2020-02-27
MX2017000821A (es) 2017-08-18
AU2022204946A1 (en) 2022-07-28
KR20170028938A (ko) 2017-03-14
MX378790B (es) 2025-03-10
JP2021006038A (ja) 2021-01-21
HUE046065T2 (hu) 2020-01-28
ZA201700344B (en) 2020-08-26
GB201615553D0 (en) 2016-10-26
PL3172227T3 (pl) 2020-04-30
LT3172227T (lt) 2020-02-10
IL250024B (en) 2020-11-30
RS59789B1 (sr) 2020-02-28
CN106795213B (zh) 2021-12-07
JP6768633B2 (ja) 2020-10-14
US20170051029A1 (en) 2017-02-23
US20190375812A1 (en) 2019-12-12
IL289475B2 (en) 2023-10-01
CN114133456A (zh) 2022-03-04
EP3172227A4 (en) 2017-12-20
MX2021000083A (es) 2021-03-25
WO2016014428A2 (en) 2016-01-28
EP3587444A1 (en) 2020-01-01
EP3172227B1 (en) 2019-09-04
EP3172227A2 (en) 2017-05-31
EA038361B1 (ru) 2021-08-13
IL250024A0 (en) 2017-03-30
US20170327555A1 (en) 2017-11-16
IL278299B (en) 2022-02-01
IL289475A (en) 2022-02-01
CN106795213A (zh) 2017-05-31
SG10202010158TA (en) 2020-11-27
KR102493543B1 (ko) 2023-01-30
SG11201700514SA (en) 2017-02-27
SI3172227T1 (sl) 2020-02-28
ES2763198T3 (es) 2020-05-27
EP3172227B9 (en) 2020-01-08
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
JP2017527272A (ja) 2017-09-21
PT3172227T (pt) 2019-12-06
CA2954847A1 (en) 2016-01-28
EA202190903A2 (ru) 2021-07-30
US20220112260A1 (en) 2022-04-14
EA201790213A1 (ru) 2017-06-30
IL289475B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US11535657B2 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
AU2015292889C1 (en) Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
EA041387B1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: QIP NOMINEES PTY LTD

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2021) APO 24: DECISION: I ALLOW THE EXTENSION OF TIME UNDER REGULATION 5.9(2)(B) FOR THE APPLICANT TO FILE THE EVIDENCE IN ANSWER UP TO 4 MAY 2021. THE CONSIDERATION OF THE STAY OF THE OPPOSITION IS CURRENTLY TAKING PLACE AND WILL BE DECIDED SEPARATELY TO THIS DECISION.

Opponent name: QIP NOMINEES PTY LTD

Effective date: 20210622

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 JAN 2022

TH Corrigenda

Free format text: IN VOL 36 , NO 15 , PAGE(S) 2171 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME DELINIA, INC., APPLICATION NO. 2015292889 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 04 MAY 2021, 27 AUG 2021 AND 31 JAN 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 04 MAY 2021, 27 AUG 2021 AND 31 JAN 2022

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2022

CFC Opposition proceedings - application withdrawn

Opponent name: QIP NOMINEES PTY LTD

MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal